REVB Stock Analysis: Buy, Sell, or Hold?
REVB - Revelation Biosciences, Inc. Common Stock
$2.03
0.13 (6.84%)
▲
WAIT
LOW Confidence
Last Updated: January 30, 2026
Earnings: Mar 05, 2026
Get Alerted When REVB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
9 traders called REVB this week
30% bullish • 21 bearish
30% bullish • 21 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: REVB is 61.1% above fair value ($1.26). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: REVB is 61.1% above fair value ($1.26). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: REVB is currently trading at $2.03, which is considered extended relative to its 30-day fair value range of $0.60 to $1.26.
Technical Outlook: Technically, REVB is in a downtrend. Immediate support is located at $0.47, while resistance sits at $2.32. The stock is showing strong short-term momentum, up 6.8% recently.
Market Sentiment: REVB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $85.00 (+4373.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, REVB is in a downtrend. Immediate support is located at $0.47, while resistance sits at $2.32. The stock is showing strong short-term momentum, up 6.8% recently.
Market Sentiment: REVB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $85.00 (+4373.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$0.60 -
$1.26
Company Quality Score
60/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
52.6%
Protect Your Profits
REVB is technically overbought (RSI 74). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+61.1% above fair value)
- BULLISH: Strong technical setup (60/100)
- BULLISH: Strong upward momentum (+6.8%)
- BULLISH: Trading 4373.7% below Wall St target ($85.00)
- WARNING: Recommendation downgraded due to 61.1% overvaluation
Fair Price Analysis
30-Day Fair Range
$0.60 -
$1.26
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$0.47
Resistance Level
$2.32
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-0.13
Wall Street Target
$85.00
(+4373.7%)
Last updated: January 30, 2026 7:45 PM ET
Data refreshes hourly during market hours. Next update: 8:45 PM
Data refreshes hourly during market hours. Next update: 8:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is REVB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 59 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1035 | 58 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$141 | 59 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
Advanced REVB Option Strategies
Professional options setups generated by AI based on today's REVB price and gamma walls.
